PRT3789 is a First-in-Human SMARCA2-Selective Degrader that Induces Synthetic Lethality in SMARCA4-Mutated Cancers.

Journal:
Cancer Research
Published:
DOI:
10.1158/0008-5472.can-25-1141
Affiliations:
7
Authors:
48
Go to article
Institutions Authors Share
Prelude Therapeutics, United States of America (USA)
41.000000
41.000000
41.000000
41.000000
41.000000
 0.85
Institute Gustave-Roussy (IGR), France
4.000000
 0.08
University of Paris-Saclay, France
1.000000
 0.02
The Wistar Institute, United States of America (USA)
1.000000
 0.02
PreludeDx, United States of America (USA)
1.000000
 0.02
Interested in Oncology and Carcinogenesis?